These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18404780)

  • 1. Erythropoietin in cancer: the new face of an old friend.
    Megalakaki C
    J BUON; 2008; 13(1):7-16. PubMed ID: 18404780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin biology in cancer.
    Hardee ME; Arcasoy MO; Blackwell KL; Kirkpatrick JP; Dewhirst MW
    Clin Cancer Res; 2006 Jan; 12(2):332-9. PubMed ID: 16428469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The erythropoietin receptor in normal and cancer tissues.
    Jelkmann W; Bohlius J; Hallek M; Sytkowski AJ
    Crit Rev Oncol Hematol; 2008 Jul; 67(1):39-61. PubMed ID: 18434185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Research advances in expression and functions of erythropoietin and erythropoietin receptor in cancers].
    Li M; Lu Y; Chen XQ
    Ai Zheng; 2008 Jun; 27(6):667-72. PubMed ID: 18570746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients.
    Sinclair AM; Todd MD; Forsythe K; Knox SJ; Elliott S; Begley CG
    Cancer; 2007 Aug; 110(3):477-88. PubMed ID: 17582631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To give or not to give recombinant EPO to anemia endangered cancer patients.
    Sulkowska M; Wincewicz A; Chabowska A; Kanczuga-Koda L; Szymanska M; Koda M; Witkowska E; Sulkowski S
    Prague Med Rep; 2006; 107(3):281-9. PubMed ID: 17385400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
    Nowrousian MR; Dunst J; Vaupel P
    Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
    Hedley BD; Allan AL; Xenocostas A
    Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
    Aapro MS; Link H
    Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pleiotropic effects of erythropoietin].
    Kes P; Basić-Jukić N; Furić-Cunko V
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():46-53. PubMed ID: 20232551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives.
    Arcasoy MO
    Clin Cancer Res; 2008 Aug; 14(15):4685-90. PubMed ID: 18676735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia.
    Osterborg A; Aapro M; Cornes P; Haselbeck A; Hayward CR; Jelkmann W
    Eur J Cancer; 2007 Feb; 43(3):510-9. PubMed ID: 17150352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events.
    Fandrey J; Dicato M
    Oncologist; 2009; 14 Suppl 1():34-42. PubMed ID: 19762515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin use in CKD patients with cancer: to tread with caution?
    Nayak-Rao S; McCormick B
    J Nephrol; 2013; 26(5):829-35. PubMed ID: 24052463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxygen breathing may be a cheaper and safer alternative to exogenous erythropoietin (EPO).
    Burk R
    Med Hypotheses; 2007; 69(6):1200-4. PubMed ID: 17493766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin has an anti-myeloma effect - a hypothesis based on a clinical observation supported by animal studies.
    Mittelman M; Zeidman A; Kanter P; Katz O; Oster H; Rund D; Neumann D
    Eur J Haematol; 2004 Mar; 72(3):155-65. PubMed ID: 14962233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle.
    Mannello F; Tonti GA
    Oncologist; 2008 Jul; 13(7):761-8. PubMed ID: 18596367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The erythropoietin receptor and its expression in tumor cells and other tissues.
    Farrell F; Lee A
    Oncologist; 2004; 9 Suppl 5():18-30. PubMed ID: 15591419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular protection by erythropoietin: new therapeutic implications?
    Joyeux-Faure M
    J Pharmacol Exp Ther; 2007 Dec; 323(3):759-62. PubMed ID: 17717190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis.
    Vaupel P
    Oncologist; 2008; 13 Suppl 3():21-6. PubMed ID: 18458121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.